Humatica advises the Riverside Company on their recent investment in Alter Pharma
By Humatica
Humatica Ltd. was retained to advise the Riverside Company on its investment in Alter Pharma, a Belgian pharmaceutical group. Alter Pharma distributes EU-sourced pharmaceutical products to wholesalers pharmacies and hospitals. It also develops and reformulates generic pharmaceuticals using GMP approved third-party manufacturers, and sells them internationally through partnerships
Humatica provided organisational due diligence services for this transaction.
To view press release: Humatica Advisor to Riverside for AlterPharma
Related News
Humatica announces promotions in London
Humatica announces promotions in London office Humatica is pleased to announce three promotions in its London office. Carlo Raco has been promoted to Director, Juan…
Read more
Humatica announces senior promotions in London and Zurich
Humatica is pleased to announce two senior level promotions, reflecting continued growth and the strengthening of its leadership team. Paul Simpson, based in Zurich, has…
Read more
Humatica once again recognised as a leader in private equity value creation by Actum in its 2026 awards
Humatica has once again been short-listed for Actum’s 2026 Value Creation Award in the People & Organisational Strategy category. This recognition reflects Humatica’s 23‑year commitment…
Read more